Pfizer (PFE) Non-Current Deferred Tax Liability (2009 - 2026)

Pfizer (PFE) has 18 years of Non-Current Deferred Tax Liability data on file, last reported at $2.4 billion in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $2.4 billion, up 6.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 6.82% YoY), and the FY2025 annual result was $2.4 billion, down 81.56% from the prior year.
• Non-Current Deferred Tax Liability steadied at $2.4 billion in Q1 2026 per PFE's latest filing, from $2.4 billion in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $13.0 billion in Q4 2024 and troughed at $558.0 million in Q3 2022.
• A 5-year average of $2.7 billion and a median of $2.2 billion in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2024: Non-Current Deferred Tax Liability plunged 93.28% in 2023, then soared 1934.84% in 2024.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $9.5 billion in 2022, then sank by 93.28% to $640.0 million in 2023, then soared by 1934.84% to $13.0 billion in 2024, then tumbled by 81.56% to $2.4 billion in 2025, then climbed by 0.46% to $2.4 billion in 2026.
• Business Quant data shows PFE's Non-Current Deferred Tax Liability at $2.4 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.5 billion in Q3 2025.